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Abstract
Chronic myeloid leukemia (CML) is a stem cell disease of the bone marrow where 
mechanisms of inter-leukemic communication and cell-to-cell interactions are pro-
posed to be important for optimal therapy response. Tunneling nanotubes (TNTs) are 
novel intercellular communication structures transporting different cargos with po-
tential implications in therapy resistance. Here, we have investigated TNTs in CML 
cells and following treatment with the highly effective CML therapeutics tyrosine ki-
nase inhibitors (TKIs) and interferon-α (IFNα). CML cells from chronic phase CML 
patients as well as the blast crisis phase cell lines, Kcl-22 and K562, formed few 
or no TNTs. Treatment with imatinib increased TNT formation in both Kcl-22 and 
K562 cells, while nilotinib or IFNα increased TNTs in Kcl-22 cells only where the 
TNT increase was associated with adherence to fibronectin-coated surfaces, altered 
morphology, and reduced movement involving β1integrin. Ex vivo treated cells from 
chronic phase CML patients showed limited changes in TNT formation similarly to 
bone marrow cells from healthy individuals. Interestingly, in vivo nilotinib treatment 
in a Kcl-22 subcutaneous mouse model resulted in morphological changes and TNT-
like structures in the tumor-derived Kcl-22 cells. Our results demonstrate that CML 
cells express low levels of TNTs, but CML therapeutics increase TNT formation in 
designated cell models indicating TNT functionality in bone marrow derived malig-
nancies and their microenvironment.
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1 |  INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloid stem cell 
disease characterized by the tyrosine kinase BCR-ABL1 
fusion protein derived from the chromosomal translo-
cation t (9;22), involving bone marrow and spleen in the 
chronic phase. Initially, CML treatment included interfer-
on-α (IFNα) and hematopoietic stem cell transplantation.1,2 
The introduction of IFNα revolutionized the treatment of 
CML and initial studies performed in 1980s by Talpaz and 
colleagues resulted in the first evidence of induced hema-
tological remission and cytogenetic responses in a subset 
of treated patients.3,4 This was the first-line treatment of 
choice for CML prior to the introduction of the tyrosine 
kinase inhibitor (TKI) imatinib in 2000, but IFNα is now 
gaining enhanced interest in combination treatments with 
imatinib and other TKIs.5 Imatinib was the first of a series 
of BCR-ABL1-targeted drugs used in treatment of CML 
patients, and these inhibitors vary based on potency, effi-
ciency on mutated ABL1 and have different adverse effect 
profiles.6-8 The role of BCR-ABL1 in microenvironment 
dependent cellular communication is less understood9-11 
particularly in the context of the efficient therapies with 
small molecule kinase inhibitors.12-14
It is well established that the tumor microenvironment 
and its cell-to-cell interactions play a pivotal role in the 
outcome of cancer therapy.15 One modality of physical cell-
to-cell interaction is the tunneling nanotube (TNT).16 TNTs 
are defined as thin (50-200 nm), fragile, and dynamic struc-
tures, consisting of plasma membrane and filamentous (F)-
actin.16,17 They are involved in cell-to-cell interaction and 
intercellular transport of organelles and pathogens such as 
virus and bacteria.16,18-24 Leukocytes, their leukemic counter-
parts and bone marrow stromal cells have all been reported to 
form TNTs in vitro.25-32 TNT is proposed to be a mechanism 
for chemo resistance by transport of oncoproteins between T 
and B cells as well as in colon cancer cells, by transfer of mi-
tochondria from endothelial cells to chemotherapy exposed 
cancer cells, or by induced drug-efflux in aggressive forms 
of pancreatic carcinoma.33-38 The impact of TNTs in vivo is 
so far not well characterized, but they have been described to 
connect myeloid cells in the cornea of mouse39,40 and in fresh 
resected tumor samples from patients with malignant pleu-
ral mesothelioma and lung adenocarcinoma.41 Subsequently, 
TNTs have been proposed to be implicated in disease and to 
play a role with respect to therapy response recently demon-
strated by vesicle exchange from stromal cells to CML cells 
providing increased resistance to imatinib.42,43
The BCR-ABL1 protein contains an F-actin binding do-
main and orchestrates several cellular processes including 
actin processing, cell attachment to fibronectin and cell mi-
gration.44 Features of CML progenitor cells from patients in 
the chronic phase include decreased adhesion and low affin-
ity to fibronectin coated surfaces compared to normal coun-
terparts.45 IFNα treatment has been demonstrated to increase 
adhesion of CML progenitor cells to bone marrow stromal 
cells.46-48 Restoration of the adhesion defect in CML cells 
seems therefore to be a significant feature of the effective 
CML therapy, recently revisited in the therapeutic combina-
tion of TKIs and IFNα eradicating CML progenitor cells re-
sulting in non-detectable disease.5,49 Here, we investigate the 
role of TKIs and IFNα treatment on TNT formation in CML 
cell models connecting TNT formation to increased cell at-
tachment to fibronectin coated surfaces.
2 |  MATERIALS AND METHODS
2.1 | Cell lines
K562, Kcl-22 (ATCC and DSMZ), and Ba/F3 cells (kind 
gift to Prof. Enserink from Dr. Gordon B. Mills laboratory, 
Portland, Oregon, USA), were routinely tested for myco-
plasma and cultured according to provider’s instructions. 
RPMI-1640 medium was supplemented with 10% of FBS, 
1% of L-glutamine (2 mM), and 1% of (1.0 U/mL) penicillin 
and streptomycin (5 mM) (Sigma-Aldrich). The RPMI-1640 
medium for the IL-3 dependent Ba/F3 cells were additionally 
supplemented with 10% conditioned medium from WEHI3B 
cells (mouse myelomonocytic cell line) known to secrete high 
concentrations of IL-3.50 The WEHI3B cells were grown to 
confluency in a T75 flask with complete IMDM medium 
(containing 10% of FBS, 1% of Pen-Strep and L-glutamine), 
and cultured for 2-3 days before the supernatant was centri-
fuged at 1500 RPM for 10 minutes and sterile filtered through 
a 0.2 µm filter.
2.2 | MemGFP, memCherry, and mitoGFP 
transduced cells
The Kcl-22(memGFP), K562(memGFP), and Kcl-
22(memCherry) cells were generated by transducing the cells 
with ready-to-use lentiviral particles expressing a membrane 
(mem) localization signal (20 amino acids of the N-terminal 
part of neuromodulin, containing a palmitoylation signal) 
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fused to GFP or Cherry; rLV-EF1-AcGFP-Mem-9 (Takara, 
rV2.1A1.1942 C2/rV2.1A1.2001 C2) and the Kcl-22(mito-
GFP) cells were generated by transducing the cells with 
ready-to-use lentiviral particles expressing a mitochondria 
targeting sequence (mito) fused to GFP; rLV.EF1.AcGFP-
Mito-9 (Takara, rV2.1A1.1941 C2) according to the provider’s 
instructions. The transduced cells were sorted using BD FACS 
Aria SORP at the Flow Cytometry Core Facility, Department 
of Clinical Science, University of Bergen, Norway.
2.3 | Primary bone marrow cells
The study was conducted in accordance with the Declaration 
of Helsinki and approved by the local Ethics Committee 
(Regional Ethics Committee West projects 2012/2245 and 
2012/2247, University of Bergen, Norway). Bone marrow 
samples from ten consecutively diagnosed CML patients 
and three healthy donors were collected after informed 
consent and were processed by density gradient separation 
(Lymphoprep, Axis-Shield, Oslo, Norway).51 For the bone 
marrow patient samples and healthy donors (Samples 5-14, 
Supplementary Table 1), hematopoietic progenitor cells were 
sorted by EasySep magnetic negative selection (StemCell 
Technologies, #19056). Briefly, both unsorted and positive 
and negative sorted cells were investigated for the presence 
of TNTs before and after treatment with nilotinib, imatinib, 
or IFNα, dependent on number of cells available after sort-
ing. Total bone marrow samples (Samples 5-10 and 13, 
Supplementary Table 1) and two positive sorted bone mar-
row samples (Samples 7 and 10, Supplementary Table 1) 
were fixed and analyzed (and reanalyzed) for the presence 
of BCR-ABL1 by fluorescent interphase in situ hybridiza-
tion (FISH). Interphase FISH analysis was performed using 
the BCR/ABL1 dual color fusion probe from Vysis Abbott 
according to manufactures instructions. Signal pattern were 
scored in 70 to 320 informative cells per sample.
2.4 | Doxycycline inducible Ba/F3 cells
BCR-ABL1 (P210) was cloned into pcDNA3 (Addgene) 
after EcoRI digestion. The orientation and sequence was veri-
fied by PCR. This was further sub-cloned into the EcoRI site 
of PLVX-tetOne-Puro (from the Lenti-X Tet-One Inducible 
Expression Systems). Ba/F3 cells were transfected with 2 µg 
of the PLVX-tetOne-BCR-ABL1 plasmid or PLVX-tetOne-
empty vector by electroporation (Amaxa biosystems nucleo-
fector II: program U20) using Ingenio Electroporation solution 
(catalog number MIR 50114). Transfected cells were cultured 
in medium for 24-72 hours before selection with 1 µg/ml puro-
mycin. Puromycin resistant clones were sorted and grown in-
dependently; cells were continually cultured in medium with 
puromycin to maintain selection pressure. Doxycycline (0.1 µg/
mL) was added to induce expression of BCR-ABL1.
2.5 | Antibodies and reagents
The following primary antibodies were used for immu-
nofluorescence and/or immunoblotting: anti-β-tubulin 
(clone TUB 2.1, Sigma-Aldrich, 1:1000), anti-COX IV 
(ab16056, 1:2500), anti-cAbl ((24-11) sc-23, Santa Cruz 
Biotechnology, 1:1000), anti-integrin β1 blocking antibody 
[P5D2] (ab24693, Abcam). Secondary antibodies used for 
immunofluorescence or immunoblotting; Alexa Fluor 488- 
or 594-conjugated goat-anti-mouse (Invitrogen, 1:5000), 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit/
mouse (Jackson Immunoresearch, 1:10 000). The follow-
ing were used for actin and membrane staining: Alexa Fluor 
350-conjugated phalloidin and wheat germ agglutinin 
(WGA)–Alexa Fluor 594 or 488 (Invitrogen) as previously 
described.31 TKIs: imatinib, nilotinib, bosutinib, ponatinib, 
and dasatinib (Selleckchem). IFNα (Intron A from MSD), 
Cytochalasin D (Sigma-Aldrich), doxycycline (Doxyferm, 
Nordic Drugs AB, Limhamn), puromycin (Sigma-Aldrich), 
Bovine serum albumin (BSA) fraction V (Roche), fibronec-
tin (Sigma-Aldrich). Optimal antibody concentrations were 
determined for all antibodies used.
2.6 | TNT identification and quantification
A TNT in this study is defined as a thin straight structure, 
≤ 200 nm in diameter, minimum 5 µm in length, hovering 
above the substratum, connecting two cells. TNTs were dis-
tinguished from cytoplasmic bridges, which appear follow-
ing cell division, by the lack of a midbody clearly visible by 
differential interference contrast and/or staining of cellular 
membranes.31 8-well µ-slides (Ibidi GmbH) were pre-coated 
with fibronectin (10  µg/mL, F2006, Sigma-Aldrich) for 30 
minutes at 37°C before washed with saline. 70 000 cells were 
seeded per well and incubated overnight under physiologi-
cal conditions. Primary CML cells were seeded in IMDM 
medium containing 20% of FBS overnight and stained with 
wheat germ agglutinin conjugated with Alexa Fluor 488 
or 594 (1.67 µg/mL) as previously described.31 Cells were 
examined live by fluorescent light microscopy (Zeiss Axio 
Observer Z1 with AxioVision 4.8.2 or Zen software) using 
a 63X/1.4 NA Oil DICIII objective, heat block (37°C) and 
standard air conditions. 100 cells per well were counted fol-
lowing a fixed counting pattern with 5-6 cells examined per 
vision field. The result is described as number of TNTs/100 
cells meaning the total number of TNTs (one TNT always 
connects two cells) among 100 cells counted. For further 
details, see Supplementary Figure in Omsland et al.31 Cell 
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viability was monitored by Hoechst 33342  nucleic acid 
stain (Sigma) as previously described (Zeiss Axio Observer 
A1with LD Plan Neofluar 20X/0.4 Corr Ph2).52
2.7 | Scanning electron microscopy (SEM)
K562 (50 000) cells were seeded onto L-lysine pre-coated 
coverslips followed by incubation at 37°C overnight be-
fore fixed (4% of glutaraldehyde in 0.2 M Na-cacodylate 
in buffer diluted 1:1 with medium) for 2 hours at RT. 
Cells were washed carefully three times for 15 minutes 
with 0.1 M Na-cacodylate buffer followed by a 60 minutes 
post-fixation with 1% of osmiumtetraoxide in 0.1 M Na-
cacodylate buffer and washed twice for 10 minutes with 
0.1 M Na-cacodylate buffer. Dehydration with ethanol was 
performed with 30% for 15 minutes, 50% for 15 minutes, 
70% for 20 minutes, or overnight, 96% for 20 minutes and 
twice with 100% for 20 minutes. The coverslips were ob-
tained from the wells and placed on SEM stubs before in-
cubated in a heat-incubator overnight. Critical point drying 
was omitted in order to avoid breakage of TNTs. The SEM 
stubs were coated with 5-10 nm gold/palladium before 
SEM microscopy.
2.8 | Mass cytometry
To reduce experiment variability and antibody consump-
tion, the commercially available metal barcoding kit from 
Fluidigm was used. After cell barcoding and washing accord-
ing to the manufacturers’ recommendations, uniquely bar-
coded samples were pooled for further processing for mass 
cytometry analysis.
The pooled cell sample was stained with a panel of 
cell surface markers (30 minutes, RT), washed using Cell 
Staining Buffer (CSB) (Fluidigm) and permeabilized with 
methanol (−20°C). After washing with CSB, the cell sam-
ple was stained with intracellular phospho-specific antibod-
ies (30 minutes, RT). The sample was washed with CSB and 
re-suspended in the buffer containing iridium-intercalator 
(natural isotopic abundance of iridium Ir191/193), which in-
tercalates iridium into the DNA (1 hours, 4°C). The sample 
was washed with CSB and pelleted by centrifugation follow-
ing incubation. Immediately prior to data acquisition cells 
were re-suspended to a final concentration of approximately 
5  ×  105 cells/mL in MaxPar water (Fluidigm) containing 
normalization beads (Fluidigm) diluted 1:10 and analyzed 
on a Helios mass cytometer (Fluidigm), placed in the Flow 
Cytometry Core Facility of Bergen, University of Bergen. 
Any drift in the data resulting from loss of detector sensi-
tivity was corrected for using the normalization bead data. 
An automatic barcode deconvolution algorithm developed by 
Zunder et al53 was used to identify each uniquely barcoded 
sample. Further discrimination and gating of single cells was 
achieved by plotting all events by DNA-content (Ir191 or Ir103) 
versus Event Length (number of pushes). Together, barcode 
deconvolution and gating of cells on DNA content versus 
event length, is an effective filter for removal of doublets and 
identification of single cells. Finally, cleaved caspase-3 read-
ily discriminated between apoptotic and non-apoptotic cells, 
where non-apoptotic cells were used for statistical analysis. 
A detailed overview of the antibody panel is described in 
Table 1.
2.9 | Blocking of β1 integrin
Cells were cultured in 6-well plates with a density of 0.7 × 106 
cells/mL. Cells were incubated in medium with or without 10 
µg/mL of anti-β1 integrin [P5D2] antibody for 30 minutes be-
fore seeded on fibronectin pre-coated µ-slides (Ibidi GmbH). 
Cells were incubated for 3 hours to allow attachment before 
treatment with 1 µM nilotinib or 100 U/mL IFNα for 1 hours 
prior to examination by live microscopy.
2.10 | Cell tracking
Measuring of cell area was performed manually using ImageJ: 
Images were analyzed as 8-bit files using FFT Bandpass Filter, 
threshold was set manually and adjusted until cells were distin-
guished from the background>convert to mask>fill holes>cells 
in close proximity were then distinguished using watershed al-
gorithm. Measuring of the cell area was performed using the 
measure tool under the region of interest manager tool and sin-
gle cells were selected using the wand tool.
Tracking of cells was performed using metamorph and 
the chemotaxis and migration (Ibidi GmbH) plugin to ImageJ 
was performed to calculate accumulated distance and to make 
trajectory plots as described by Hurley et al.54
2.11 | Immunofluorescence
The presence of F-actin and/or microtubules in TNTs was 
investigated in Kcl-22 cells (on 8-well µ-slides, Ibidi GmbH) 
fixed in 4% of PFA in PBS and 0.2% of glutaraldehyde in 
PBS for 20 minutes at room temperature (RT) followed by 
one wash with PBS, before permeabilized for 1 minute using 
0.2% of Tween in PBS and washed twice with PBS. Cells 
were blocked with 0.5% of BSA PBS for 20 minutes at RT 
and then incubated for 1 hour at RT in the dark with 33 nM 
Alexa Fluor phalloidin, washed once with PBS and incu-
bated with anti-β-tubulin antibody (1:200 in blocking solu-
tion) overnight at 4°C. Then cells were washed twice with 
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PBS and incubated with Alexa Fluor-488 or Alexa Fluor-594 
goat-anti-mouse antibodies (1:5000 in blocking solution) for 
1 hour at RT, before washed twice with PBS and examined 
by fluorescence microscopy. Cells not expressing memGFP 
were stained with wheat germ agglutinin (WGA) conjugated 
with Alexa Fluor-488 or Alexa Fluor-594 for 8 minutes fol-
lowed by one wash with PBS before examined by micros-
copy and manual quantification of TNTs.
2.12 | Immunoblotting
Cells were lysed and analyzed by immunoblotting according 
to standard protocol.55,56 Briefly, immunobloting was per-
formed using precast gels from BioRad, transferred to PVDF 
membranes using Pierce G2 fast blotter (Thermo Scientific). 
Membranes were blocked for 1  hours at RT in 5% of fat-
free dry-milk or 5% of BSA in TBST, incubated with pri-
mary antibody at 4°C overnight. Membranes were washed 
with TBST followed by incubation for 1 hour with second-
ary antibody ([HRP]-conjugated goat-anti-rabbit/mouse) 
was diluted 1:1000 in 5% of drymilk in TBST and washed 
with TBST before developed using SuperSignal West pico or 
femto (Thermo Fisher Scientific). Developed immunoblots 
were detected and captured by ImageQuant LAS 4000 (GE 
Healthcare Life Sciences).
2.13 | Transfer assay
Kcl-22(memCherry) cells (35  000) and Kcl-22(mitoGFP) 
cells (35 000) were seeded on a fibronectin pre-coated 8-well 
µ-slides (IBIDI) and treated with 100 U/mL IFNα for 24 
hours before fixation with 4% of PFA for 15 minutes at room 
temperature in the dark. The experiment was performed in 
duplicates and in total six images was obtained from each 
well and presence of memCherry or mitoGFP was counted.
2.14 | Animal studies
2.14.1 | NSG (NOD/SCID IL2rγnull) mice
The protocol for animal studies was approved by the 
Norwegian State Commission for Laboratory Animals 
(FOTS approval number: 20158178) and the experiments 
were performed according to the European Convention for 
the Protection of Vertebrates Used for Scientific Purposes. 
T A B L E  1  Antibody panel for mass cytometry
A.m.u Metal Epitope Clone Vendor
102 Pd Metal Barcode Channel #1 N.A. Fluidigm
104 Pd Metal Barcode Channel #2 N.A. Fluidigm
105 Pd Metal Barcode Channel #3 N.A. Fluidigm
106 Pd Metal Barcode Channel #4 N.A. Fluidigm
108 Pd Metal Barcode Channel #5 N.A. Fluidigm
110 Pd Metal Barcode Channel #6 N.A. Fluidigm
89 Y CD45 HI30 Fluidigm
141 Pr pBCR Y177 Polyclonal CST
142 Nd Caspase 3 Cleaved D3E9 Fluidigm
143 Nd pCrkL [Y207] Polyclonal Fluidigm
149 Sm p4E-BP1 236B4 Fluidigm
150 Nd pStat5 [Y694] 47 Fluidigm
153 Eu pStat1 [Y701] 58D6 Fluidigm
154 Sm pAbl Y245 73E5 CST
156 Gd p-p38 [T180/Y182] D3F9 Fluidigm
158 Gd pStat3 [Y705] 4/P-STAT3 Fluidigm
165 Ho pCREB [S133] 4/P-STAT3 Fluidigm
167 Yb pERK 1/2 [T202/Y204] D1314.4E Fluidigm
172 Yb pS6 [S235/S236] N7-548 Fluidigm
176 Yb pS6 [S240/S244] D68F8 CST
191 Ir DNA N.A. Fluidigm
193ß Ir DNA N.A. Fluidigm
Abbreviations: A.M.U, atomic mass unit; CST, cell signaling technology; Metal, rare metal isotopes.
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NSG mice (6-8 weeks old; Vivarium, University of Bergen) 
were maintained under defined flora conditions in individu-
ally ventilated cage on a 12 hours dark/night schedule at a 
constant temperature of 21°C and at 50% relative humidity. 
Bedding and cages were autoclaved and changed twice per 
month. The mice had continuous supply of sterile water and 
food and were monitored daily by the same personnel for the 
duration of the experiment.
2.14.2 | Orthotopic xenograft model of  
Kcl-22
Female NSG mice (n = 3 mice per group) were intravenously 
inoculated with 5 × 106 Kcl-22 cells via tail-vein, using a 30-
gauge insulin needle. Cells were administered as a suspension 
in phosphate-buffered saline at a concentration of 5  ×  107 
cells/mL. Mice (n = 3) were dosed for 20 days b.i.d, with 20 
mg/Kg nilotinib (Novartis Pharma), starting day seven from 
injection of leukemic cells. The nilotinib solution (0.5% of 
HPMC and 0.05% of Tween 80 in water) was administrated 
orally (4 mg/mL) using a Teflon coated needle. Control mice 
received a similar volume of vehicle. All animals were ob-
served thrice weekly for anemia, dehydration, and weight 
loss. Fluorescence imaging was used to determine the degree 
of infiltration with leukemic cells, 30 days after injection. 
For near infrared time-domain imaging,57 a cocktail of 3 dif-
ferent fluorescently labeled monoclonal antibodies (CD45, 
CD13, and HLA-ABC) was administrated to each animal via 
tail-vein, 24 hours prior to imaging, in a total concentration 
of 1 μg/g. Briefly, mice were anesthetized with Isoflurane 
(Isoba Vet 3%, Intervet), depilated and whole-body imaging 
was performed with an Optix MX3 Small Animal Molecular 
Imager (ART Inc., Saint-Laurent, QC, Canada). All images 
were acquired with Optix Optiview (ART Inc.) acquisition 
software (version 2.00) and analyzed using Optix Optiview 
(version 2.02.00, ART Inc.).
2.14.3 | Subcutaneous xenograft model of 
Kcl-22
NSG mice (n = 5) were subcutaneously injected in the left 
flank area with 5  ×  106 Kcl-22(memGFP) cells in 100  µL 
solution of PBS containing 10% of Matrigel (BD Matrigel 
Basement Membrane Matrix, BD Biosciences). The health 
status and weight of the mice were monitored daily. When 
tumor volumes reached 180-350 mm3 (day 12), the mice 
were divided into two groups and treated orally q.d. for five 
days with either nilotinib 10 mg/kg or control, injections of 
0.5% of HPMC and 0.05% of Tween 80 in water solution 
once daily. Tumor volumes were measured every second 
day by a digital caliper using the ellipsoid volume formula: 
Volume = π (length × width × height)/6. Non-fixed live tu-
mors were sliced into 100 µm thick slices using the motorized 
vibroslicer NVSLM1 (WPI) and added in an IBIDI 8 µ-well 
in IMDM medium before microscopy. For SEM samples, 
whole tumors were placed in 15 mL tubes and fixed in 4% of 
PFA at 4°C over night before prepared for SEM as described 
above for Kcl-22 cells on coverslips.
2.15 | Statistical analysis
Differences between two groups were analyzed by two-tailed 
unpaired t test using GraphPad Prism 6 Version 6.03. F test 
was performed to verify that the internal variance in the 
groups were not significant. Significant difference was con-
sidered by a P-value < .05. For multiple comparisons of the 
effect of TKIs, a two-way ANOVA with Dunnett’s multiple 
comparisons test was used. One-way ANOVA with Tykey’s 
multiple comparisons test was used for investigation of sig-
nificant changes in the Ba/F3 cells. For cell area and cell 
movement, unpaired Mann-Whitney tests were performed.
3 |  RESULTS
3.1 | Effects of tyrosine kinase inhibitors 
(TKIs) on TNT formation in CML cell lines
In order to study the presence of TNTs in the CML cell lines 
K562 and Kcl-22, they were stably transduced to express cel-
lular membrane localized GFP (memGFP) and cultured with 
and without drug treatment on fibronectin coated surfaces. To 
investigate the effects of TKIs on TNT formation, the K562 
and Kcl-22 cells were treated with pre-apoptotic concentra-
tions of imatinib, nilotinib, bosutinib, ponatinib, or dasat-
inib (Figure 1A), kinase inhibitors currently in use as CML 
therapy.58 TNT quantification was performed as earlier de-
scribed for acute myeloid leukemia (AML) cells.31 The K562 
and Kcl-22 cells formed very low numbers of TNTs without 
treatment (Figure 1A), however, 24 hours imatinib treatment 
resulted in a significant increase in TNT formation in both 
K562 (2.67 to 8.5 TNTs/100 cells, P-value <.001) and Kcl-
22 cells (0.16 to 5.67 TNTs/100 cells P-value < .001) (Figure 
1A). TNT formation following treatment with nilotinib, bosu-
tinib, ponatinib, or dasatinib caused a variable TNT response 
between the K562 and Kcl-22 cell lines (Figure 1A). Nilotinib 
treatment increased TNT formation in Kcl-22 cells only (0.16 
to 5.5 TNTs/100 cells, P-value < .001) while ponatinib sig-
nificantly increased TNT formation in K562 cells only (2.67 
to 7.5 TNTs/100 cells, P-value < .001). Interestingly, neither 
bosutinib nor dasatinib induced a significant increase in TNT 
formation in K562 or Kcl-22 cells (Figure 1A). A closer ex-
amination of K562 cells after imatinib treatment by scanning 
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electron microscopy showed thin TNT structures (Figure 1B). 
To evaluate if the effect of TKIs on intracellular signal trans-
duction targets could provide an explanation with respect to 
the heterogeneous dynamics of TNT formation in K562 and 
Kcl-22 cells, both cell lines were treated with the various 
TKIs for 24 hours and known alterations in central signal-
ing pathways known to be downstream of BCR-ABL159 were 
analyzed using mass cytometry.60 As expected after TKI 
treatment, we observed a marked reduction in phosphoryla-
tion of several ABL1 downstream signaling targets including 
F I G U R E  1  Effect of TKIs on TNT formation and intracellular signaling in CML cell lines. A, Kcl-22(memGFP) and K562(memGFP) cells 
were untreated (Ctr) or treated with 5000 nM imatinib, 1000 nM dasatinib, 100 nM nilotinib, 1 nM ponatinib, and 1 nM bosutinib for 24 hours. 
Percentage abnormal nuclei relative to Ctr cells calculated from Hoechst 33342 staining and manual counting is shown below. B, Scanning electron 
microscopy (SEM) image of a TNT connecting K562 cells that had been treated with 5000 nM imatinib for 24 hours. Jeol JSM-7400F LEI 4.0kV 
X3,700 WD 8.0 mm, scale bar = 1 µm. C, Mass cytometry analysis of down-stream signaling pathways of BCR-ABL1 in K562 and Kcl-22 cells 
treated with the TKIs as described in (A). Results are illustrated by fold changes relative to control (all gated for live cells) based on calculated 
Arcsinh Ratio of Medians, median from three independent experiments are shown. D, K562(memGFP) and Kcl-22(memGFP) cells were untreated 
(Ctr) or treated with 100 nM nilotinib (Nilo) for 1 hour. For all displayed graphs: Mean ±standard deviation (S.D.) used together with a two-
way ANOVA with Dunnett’s multiple comparison for (A) and unpaired t tests for (D) (***P < .001, **P < .005, n.s = not significant). All TNT 
quantifications were performed at least three independent times unless otherwise noted. Fluorescence microscopy was performed by the use of 
Zeiss AxioObserver Z1 fluorescence microscope with Alpha Plan Apochromat 63X/1.4 NA Oil DICIII and Zeiss Axio Observer A1with LD Plan 
Neofluar 20X/0.4 Corr Ph2
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CrKL-(Tyr207), STAT5-(Tyr694) and RPS6 (Ser235/236 
and Ser240/244) (Figure 1C). Also, phosphorylation of p38-
(Thr180/Tyr182) and STAT3-(Tyr705) were reduced in 
the two cell lines, but there were no obvious differences in 
therapy response in the proteins investigated that could pro-
vide insight to the observed heterogenous dynamics of TNT 
formation in K562 and Kcl-22 following nilotinib treatment. 
Treatment with imatinib or nilotinib in both cell lines induced 
almost identical changes in the studied signal transduction 
phospho-proteins but differed in TNT formation follow-
ing nilotinib treatment. This was also compared following 
one-hour treatment with pre-apoptotic concentration of nilo-
tinib. Similar to 24 hours treatment a significant increase in 
TNT formation was observed in the Kcl-22 cell lines not 
found for the K562 cells (Figure 1D).
3.2 | The TNTs formed after nilotinib 
treatment contains actin
The TNT structures connecting the Kcl-22 cells both without 
any treatment and after treatment with imatinib or nilotinib, 
were verified not to be in contact with the substratum by z-
stack imaging (x,z) (Figure 2A). In all experiments including 
Kcl-22 treated with nilotinib for 1 or 24 hours treatment, we 
observed a dramatic change in cell morphology from spheri-
cal semi-attached cells to firmly attached fibroblast-like 
cells, which was less evident in K562 cells (Figure 2B). The 
TNTs formed in nilotinib-treated Kcl-22 cells were further 
verified by immunofluorescence for the presence of F-actin 
and absence of β-tubulin (Figure 2C). The importance of 
F-actin in the TNT structures was next examined by treat-
ment with the actin polymerization inhibitor cytochalasin D 
(CytD).18,61 Kcl-22 cells were treated for 24 hours with nilo-
tinib and quantified for TNTs before treatment with CytD for 
20 minutes followed by a second TNT quantification (Figure 
2D). This demonstrated that CytD blocked TNT formation in 
nilotinib treated cells and, interestingly fluorescent imaging 
showed less prominent change in cell morphology after nilo-
tinib treatment (Figure 2E).
F I G U R E  2  TNT increases following nilotinib treatment 
in actin dependent manner. A, Z-stack of TNTs connecting Kcl-
22(memGFP) cells untreated (Ctr) or treated with nilotinib (Nilo, 
100 nM) or imatinib (Ima, 5000 nM) for 24 hours. X-Z projection 
obtained from ImageJ are shown below. B, Fluorescence microscopy 
of K562(memGFP) and Kcl-22(memGFP) cells untreated (Ctr) or 
treated with nilotinib (Nilo, 100 nM) for 1 hours. C, Kcl-22(memGFP) 
cells were treated with nilotinib (Nilo, 100 nM) for 1 hours, fixed and 
stained with phalloidin (F-actin) AF350 followed by anti-β-tubulin 
staining. Representative images of three independent experiments 
are shown. D, Kcl-22(memGFP) cells were untreated or treated 
with nilotinib (Nilo, 100 nM) for 24 hours and TNT quantification 
was performed before and after addition of cytochalasinD (CytD, 
2 µM) for 20 minutes, at 37°C. E, Representative fluorescence 
images from three independent experiments performed in duplicate 
of Kcl-22(memGFP) cells with no treatment (Ctr) or treatment with 
nilotinib (Nilo, 100 nM), cytochalasin D (CytD, 2 µM), or nilotinib 
(Nilo, 100 nM) followed by cytochalasin D (CytD, 2 µM). For all 
displayed graphs: Mean ± standard deviation (S.D.) used together 
with unpaired t tests (**P < .005, ***P < .001, n.s = not significant). 
All TNT quantifications were performed at least three independent 
times. Fluorescence microscopy was performed by the use of 
Zeiss AxioObserver Z1 fluorescence microscope with Alpha Plan 
Apochromat 63X/1.4 NA Oil DICIII. Scale bars = 10 µm 
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3.3 | IFNα increases TNT formation and 
membrane exchange in Kcl-22 cells
Since IFNα has been reported to increase adhesion of CML 
progenitor cells to bone marrow stromal cells and fibronectin 
coated surfaces,46,48 it was of interest to investigate the ef-
fect of IFNα on TNT formation in K562 and Kcl-22 cells. 
Following treatment for 24 hours, TNT formation was signif-
icantly increased in Kcl-22 cells (0.8 TNTs/100 cells to 6.8 
TNTs/100 cells, P-value < .005) compared to K562 cells (3.8 
TNTs/100 cells to 2.3 TNTs/100 cells) (Figure 3A), similar 
to that observed after nilotinib treatment.
Interestingly, time-lapse microscopy of Kcl-22 cells fol-
lowing 1 hour treatment with IFNα visualized GFP positive 
objects moving along the TNTs, from one cell to another, 
indicating functional properties of the TNTs in Kcl-22 cells 
(Figure 3B and Supplemental Video S1). To further inves-
tigate, membrane and/or mitochondria exchange following 
IFNα treatment, a coculture of Kcl-22(memCherry) and Kcl-
22(mitoGFP) was established. TNTs were observed connect-
ing the memCherry and mitoGFP positive cells (Figure 3C) 
and a significant increase in memCherry positive membrane 
parts present in Kcl-22(mitoGFP) cells were observed, while 
no mitochondria in form of mitoGFP was observed in any of 
the mem-Cherry positive cells (Figure 3D,E, P-value < .005 
and data not shown).
3.4 | Expression of BCR-ABL1 in Ba/F3 
cells results in cell rounding
Since imatinib increased TNT formation in the BCR-ABL1 
positive cell lines K562 and Kcl-22, we further investigated the 
role of BCR-ABL1 in the formation of TNTs. For this purpose, 
we utilized the murine pro B cell line Ba/F3. The Ba/F3 cells 
represent a well explored system for characterization of the 
oncogene function of BCR-ABL1, where expression of BCR-
ABL1 allows Ba/F3 cells to proliferate independent of IL-3.62 
A doxycycline (dox) inducible BCR-ABL1 protein system was 
introduced in the Ba/F3 cells by electroporation and puromy-
cin selection and was compared with an empty vector control 
(E.V.).63 The induction of BCR-ABL1 expression by dox was 
verified by immunoblotting and IL-3-independent proliferation 
(Figure 4A,B). To visualize membranes and TNT formation, 
the cells were stained with WGA-488 before live cell fluores-
cence microscopy. In the Ba/F3 cells, dox-induced BCR-ABL1 
expression resulted in a change from mostly semi-adherent 
and non-spherical morphology to spherical morphology with 
a reduced attachment to the fibronectin surface. In comparison, 
the imatinib treated BCR-ABL1 expressing cells displayed no 
change in cell morphology compared to the BCR-ABL1 in-
duced control cells (Figure 4C). Interestingly, expression of 
BCR-ABL1 was accompanied by a tendency of reduced TNT 
formation, although not significant (Figure 4D). This was not 
due to the dox treatment, since dox treatment of Ba/F3 control 
cells (E.V.) resulted in an increase of TNT formation (Figure 
4D). Increase in TNT formation after imatinib treatment was 
only present in the Ba/F3 cells not expressing BCR-ABL1. 
When BCR-ABL1 expression was induced, TNT numbers 
were decreased following imatinib treatment (Figure 4D). TNT 
structures were imaged in the Ba/F3 cells expressing the empty 
vector (E.V.) or doxycycline inducible BCR-ABL1 at basal 
level and treated with doxycycline (Figure 4E).
3.5 | TNT formation and increased cell 
surface adhesion by drug treatment
Cell adherence to fibronectin has previously been found to 
correlate with TNT formation30 and treatment of CML cells 
with IFNα and TKIs have been shown to increase cell adher-
ence to fibronectin, described through a restoration of the β1 
integrin by IFNα.46,48,64,65 To study the role of β1 integrin in 
cell adherence and TNT formation, we pre-incubated Kcl-22 
cells for 30 min with a β1 integrin blocking antibody before 
treatment for one hour with either IFNα (100 U/mL ) or nilo-
tinib (1 µM). The Kcl-22 cells, without pre-incubation with 
the β1 integrin blocking antibody (Ctr), showed transformed 
cell morphology and significantly increased cell surface area 
on the fibronectin coated surface following nilotinib treat-
ment, whereas IFNα treatment resulted in altered morphology 
only without significant changes in cell surface area (Figure 
5A,B). Strikingly, these cell morphology changes after nilo-
tinib and IFNα treatment were completely abolished by pre-
incubation with the β1 integrin blocking antibody (Figure 
5A,B). In support of this, cell movement was investigated 
by time-lapse microscopy, where the images were acquired 
every 10th second for a total 2 min for each duplicate, dem-
onstrating that the IFNα and nilotinib-induced changes in cell 
morphology was followed with a decrease in cell movement 
(Figure 5C,D and Supplemental videos 2-7). Conversely, pre-
treatment with the β1 blocking antibody resulted in increased 
cell movement (representative videos shown in Supplemental 
videos 2-7). These observed changes were quantified by 
tracking the distance of movement by the cells in the time 
lapse-videos and resulted in significant increase in distance 
when cells were treated with β1  integrin blocking antibody 
(Figure 5C,D).
3.6 | Nilotinib treatment in a subcutaneous 
Kcl-22 mouse model causes cellular 
morphology changes
Initially the efficacy of nilotinib was investigated in an or-
thotopic xenograft mouse model of Kcl-22. Fluorescence 
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imaging of mice treated per oral for 20 days with nilotinib 
(10 mg/kg, b.i.d.) starting at day 7, showed great efficacy 
of the treatment at day 30 compared to the control vehicle 
(0.5% of hydroxypropyl methylcellulose (HPMC) and 0.05% 
of Tween 80 in water solution) treated mice and infiltration 
of leukemic cells was visible only in the superficial lymph 
F I G U R E  3  IFNα treatment increases TNT formation and membrane exchange in Kcl-22 cells. A, Number of TNTs were quantified in 
K562(memGFP) and Kcl-22(memGFP) cells treated with interferon-α (IFNα, 100 U/mL) (+) for 24 hours compared to untreated (−). B, Time-
lapse of Kcl-22(memGFP) cells treated with IFNα (100 U/mL) for 1 hour where images were captured every 10th second for a total of 120 
seconds. Arrow heads indicate movement of memGFP along the TNT structure over time. C, Coculture of Kcl-22(memCherry) (35 000 cells) and 
Kcl-22(mitoGFP cells) (35 000 cells) treated with IFNα (100 U/mL) for 24 hours. Arrows indicate TNT connection between the two cell lines. 
D, Red dots indicated by arrowheads demonstrate memCherry transferred from Kcl-22(memCherry) cells to Kcl-22(mitoGFP) cells in untreated 
control cells and IFNα treated cells. E, Significant presence of memCherry in Kcl-22(mitoGFP) cells after 24 hours coculture and IFNα treatment. 
Experiments were performed in duplicates and repeated in two independent experiments. A total of 189 cells were included in the control while 
196 cells where counted in the IFNα treatment. Scale bar = 10 µm. For all displayed graphs: Mean ± standard deviation (S.D.) used together with 
unpaired t tests (**P < .005, n.s = not significant). All TNT quantifications were performed at least three independent times unless otherwise noted. 
Fluorescence microscopy was performed by the use of Zeiss AxioObserver Z1 fluorescence microscope with Alpha Plan Apochromat 63X/1.4 NA  
Oil DICIII
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F I G U R E  4  Effects of BCR-ABL1 expression on TNT formation and cell morphology in Ba/F3 cells. A, Ba/F3 cells transfected with empty 
vector (E.V.) or BCR-ABL1 were untreated (−) or treated (+) with doxycycline (0.1 µM) for 24 hours, lysed and immunoblotted using anti-c-Abl 
antibody to verify BCR-ABL1 expression. K562 cells were used as positive control for BCR-ABL1 expression and COXIV as loading control. 
B, Validation of IL-3 independence following BCR-ABL1 expression. Representative images captured by phase/contrast light microscopy. Scale 
bars = 10 µm. C, Fluorescence microscopy images of Ba/F3-BCR-ABL1 doxycycline inducible cells cultured in the presence or absence of IL-3 
and without (−Dox) or with doxycycline (+Dox, 0.1 µM) stained with WGA-488. Scale bars = 10 µm. D, TNT quantification of Ba/F3-E.V. and 
Ba/F3-BCR-ABL1 cells cultured in the presence (+) or absence (−) of IL-3 with (+) or without (−) doxycycline (+Dox, 0.1 µM), and with (+) or 
without (−) imatinib (Ima, 5000 nM). For selection, 1 µg/mL puromycin was present in the culture media in all conditions. Percentage abnormal 
nuclei relative to control following Hoechst 33342 staining is shown below. E, Fluorescence microscopy of Ba/F3-E.V. or Ba/F3-BCR-ABL cells 
with doxocycline (+Dox) or without (−Dox). Cells were stained with WGA-488. Arrow heads indicate TNT connections. Scale bar = 10 µm. 
Microscopy was performed using Zeiss AxioObserver Z1 fluorescence microscope with Alpha Plan Apochromat 63X/1.4 NA Oil DICIII and 
Zeiss Axio Observer A1with LD Plan Neofluar 20X/0.4 Corr Ph2. All data are presented as mean ± standard deviation (S.D.) and investigated for 
significance by one-way ANOVA with Tykey’s multiple comparisons test. All experiments were performed three times except TNT quantification 
of Ba/F3 treated with doxocycline and incubated without IL-3 (n = 2)
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nodes and gastrointestinal tract of the untreated mice (Figure 
6A,B). The treatment was well tolerated since no changes 
in weight were observed between mice treated with nilotinib 
and controls (Figure 6C). Efficacy of treatment was also 
confirmed by survival where the control mice had a median 
survival of 34 days, while the treated animals lived disease 
free for more than 90 days (Figure 6D).
In further attempts to examine TKI modulations of TNTs 
and cell morphology in vivo, we compared Kcl-22(memGFP) 
cells derived from a subcutaneous mouse model following 
F I G U R E  5  Adherence to fibronectin enhances TNT formation and reduces cell movement in Kcl-22 cells. A, Kcl-22(memGFP) cells were 
pre-treated for 30 minutes with anti-β1 integrin blocking antibody (10 µg/mL) before seeded onto fibronectin-coated IBIDI wells, allowed to adhere 
for 3 hours before treated for 1 hour with IFNα (100 U/mL) or nilotinib (Nilo, 1 µM) (lower panel). This was compared to cells not pre-treated with 
anti-β integrin blocking antibody (upper panel). Cells were investigated by fluorescence microscopy. Scale bars = 10 µm. B, Cell area (µm2) of 
experiments in (A) was measured manually using ImageJ. C, Cells seeded on fibronectin were tracked for migration (µm) by live cell imaging and 
analyzed using metamorph and measurements were calculated using Chemotaxis and Migration (IBIDI) plugin in ImageJ. D, Statistical analysis of 
migration of the Kcl-22(memGFP) cells following the different treatment conditions. Significance of changes was calculated using unpaired Mann-
Whitney test. Mean ±standard deviation (S.D.) (*P < .05, ***P < .001, n.s = not significant). Results are presented as mean ±standard deviation 
(S.D.) and significance investigated by the use of unpaired t tests (***P < .001, n.s = not significant). Microscopy was performed using Zeiss  
AxioObserver Z1 fluorescence microscope with Alpha Plan Apochromat 63X/1.4 NA Oil DICIII 
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F I G U R E  6  In vivo effect of nilotinib on Kcl-22 cells in a subcutaneous xenograft tumor model. A, Time-domain fluorescence imaging 
results for mice injected i.v. with Kcl-22 cells. Vehicle (Ctr) treated mice (two mice imaged) versus mice treated with nilotinib (Nilo, 20 mg/
kg b.i.d. per oral) for 20 days with start day 7. Superficial lymph nodes and gastro-intestinal (G.I.) tract infiltration are visible in the control 
group, while the treated mice present only background fluorescence. i.v: intravenously, b.i.d: twice daily, PC: photon counts. B, Fluorescence 
quantification (PC/sec) of (A) a significant reduction in nilotinib (Nilo) treated mice compared to vehicle (Ctr) treated (*P < .05). C, Weight 
changes in vehicle (Ctr) treated mice and nilotinib (Nilo) treated mice. D, Survival curves for vehicle (Ctr) treated mice and mice treated with 
nilotinib (Nilo) in the orthotopic Kcl-22 xenograft model. E, Five mice were injected subcutaneously with Kcl-22(memGFP) cells and matrigel. 
At day 12, three mice with similar tumor size (average of 184 mm3) were treated once per day for 5 days with nilotinib (Nilo, 10 mg/kg) and two 
mice with similar size tumors (average of 334 mm3) were vehicle (Ctr) treated. Tumor volumes were measured at day 1 and day 4. At day 5, the 
mice were treated 1 hour prior to euthanization and collection of tumors. F, Live tumor sections (100 µm) were performed by the use of Vibroslice 
and tumor derived memGFP positive cells from nilotinib (Nilo) and vehicle (Ctr) treated mice were investigated by confocal microscopy using 
the Leica TCS SP5 confocal microscope with the resonant scanner and the 63 × /1.40 NA oil-immersion objective. Scale bar = 10 µm. G) Tumor 
sections (100 µm) from nilotinib (Nilo) and vehicle (Ctr) treated mice were fixed, prepared for and analyzed by scanning electron microscopy 
Jeol JSM-7400F LEI 4.0kV X3, 700 WD 8.0 mm. Scale bar = 1 µm. For all: Mean ± standard deviation (S.D.) is demonstrated in the graphs and 
significance investigated by the use of unpaired t test
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treatment with and without nilotinib. At day 12 after injection 
with Kcl-22(memGFP) cells three mice with similar tumor 
volumes (average tumor volume 184 mm3) and two mice 
with similar volumes (average tumor volume 335 mm3) were 
treated per oral with nilotinib (10 mg/kg g.d.) or vehicle con-
trol (0.5% of HPMC and 0.05% of Tween 80 in water solu-
tion) for 5 days (Figure 6E). On day 5 of treatment, tumors 
were collected one hour after nilotinib and vehicle adminis-
tration. Confocal fluorescence microscopy of non-fixed live 
vibratome sliced tumor sections indicated increased num-
ber of TNT-like structures in the tumors from the nilotinib 
treated mice as compared to vehicle treated mice (Figure 6F). 
When the cells retrieved from the tumors were examined by 
scanning electron microscopy (SEM), a difference in cell 
morphology and TNT-like structures was evident in the tu-
mors from untreated and nilotinib treated mice (Figure 6G).
3.7 | TKI or IFNα treatment of CML 
chronic phase derived bone marrow patient 
cells do not result in morphology changes or 
increased number of TNTs
To characterize the basal level of TNTs on primary CML 
cells, fresh bone marrow cells from four chronic phase CML 
patients were stained with WGA-594 and examined by live 
microscopy (Samples 1-4, Supplemental Table 1). Similar 
to the CML cell lines, these cells formed few or no TNTs 
(Supplemental Figure 1A). To further examine the effect of 
TKIs or IFNα treatment on primary patient derived cells, 
cryopreserved bone marrow-derived cells from six chronic 
phase CML patients and three healthy donors were thawed 
(Samples 5-13, Supplemental Table 1) and these cells were 
treated with nilotinib (1 µM), IFNα (100 U/mL) or imatinib 
(5 µM) for 24 hours before examined for morphological 
changes and TNT formation compared to untreated cells. In 
these cells, no changes in morphology or movement were ob-
served in the CML patient-derived or healthy cells after nilo-
tinib or IFNα treatment and no or few TNTs were observed 
(Supplemental Figure 1B-D). Following this, we aimed to 
purify hematopoietic progenitor cells by the use of negative 
selection using (EasySep Human progenitor cell Enrichment 
Kit, magnetic beads coated with antibodies targeting non-
progenitor cells with CD2, CD3, CD14, CD16, CD19, CD24, 
CD66b, glycophorin A) for three CML patient samples and 
one healthy bone marrow sample. The negative selected and 
positive selected cells were treated with nilotinib (1 µM) and 
if sufficient number of cells, with IFNα (100 U/mL) for 24 
hours, however; no changes in morphology or reduced mo-
bility were found for either the negative or positive sorted 
cells and few or no TNTs (Supplemental Figure 1E). The 
CML patient cells, including two positive sorted samples 
(Samples 6 and 7), and one healthy bone marrow sample 
(negative control) were analyzed by FISH for reverification 
of BCR-ABL1 showing that BCR-ABL1 was expressed in 
both the total bone marrow sample as well as in the positive 
sorted cells, whereas the healthy bone marrow sample was 
negative for BCR-ABL1 (Supplemental Figure 1F).
4 |  DISCUSSION
TNTs are highly dynamic intercellular communication struc-
tures consisting of plasma membrane and F-actin, however, 
the detailed understanding of TNT regulatory mechanisms 
are still limited.66-68 Since the tyrosine kinase ABL1 and the 
oncogenic fusion protein BCR-ABL1 include distinct F- and 
G-actin binding domains with actin bundling activity,69 we 
examined various BCR-ABL1 expressing cells with respect 
to TNT formation. BCR-ABL1 positive CML cells, cell 
lines, and patient-derived cells, displayed limited numbers or 
absence of TNT formation compared to acute myeloid leu-
kemia cells, stromal cells and other cancer cells.30,31,41,70,71 
TNT formation between cells in vitro is highly dependent 
on adherence, and culturing leukocytes on a supportive layer 
of mesenchymal stem cells (MSCs) or fibronectin increases 
TNT formation.30,72 The limited TNT numbers observed in 
our study is supported by Kolba and coworkers also report-
ing limited TNTs formed by K562 cells43 and this could be 
related to the observation that primary CML cells have adhe-
sion defects and thus adhere poorly to bone marrow stroma,9 
which consequently may result in a lack of TNT formation 
and cellular communication.
Interestingly, we find both increased adhesion and a 
change in morphology in the CML cell line Kcl-22 following 
treatment with imatinib, nilotinib, or IFNα accompanied by 
a significant increase in TNT formation (Figures 1A, 2A,B, 
and 3A). IFNα was the first effective CML therapy and is 
now re-evaluated in combination with TKIs for more rapid 
disease control and possibly cure.49,73 One of the proposed 
mechanisms for the efficacy of IFNα in treatment of CML 
patients is indeed through restored adhesion of CML cells to 
the bone marrow stroma.74 Similarly, TKI treatment has been 
reported to increase CML cell adherence to fibronectin.64 
Together, these observations suggest that increased adherence 
of CML cells could play a role in treatment of CML patients. 
The functionality of the IFNα-enhanced TNTs was examined 
by live-cell microscopy where memGFP were found to be 
transported between Kcl-22 cells, suggesting that the TNTs 
formed after IFNα treatment could be functional as trans-
portation devices. This transport was further investigated by 
coculturing Kcl-22 cells(mitoGFP) and Kcl-22(memCherry) 
following treatment with IFNα where these cells were con-
nected by TNTs and memCherry was significantly increased 
in the Kcl-22(mitoGFP) cells (Figure 3C-E). This could be 
explained by other means of transportation or cell-to-cell 
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communication besides TNT formation, but TNTs could play 
an important role in IFNα induced cell-to-cell communica-
tion, possible also involving the bone marrow microenviron-
ment as demonstrated by Kolba and coworkers.43
In order to search for a possible link between TNT, 
BCR-ABL1, and actin, we studied the activity of the three 
GTPases Rac1, Rho, and Cdc42 by the use of a pull-down 
and activity detection in K562 and Kcl-22 cells (data not 
shown). However, we did not find that the treatment resulted 
in changes in the GTPase activity of these three GTPases. A 
reduction in the total protein of the Rac1 guanine exchange 
factor (GEF) protein Tiam-1 was found following imatinib 
and nilotinib treatment in the Kcl-22 cells, but not in the 
K562 cells (data not shown). Elevated levels of Tiam-1 have 
been associated with increased migration and metastasis in 
colon tumor cells.75 In our hands, no consistent G-protein 
modulation could explain the nilotinib TNT-response in the 
Kcl-22 cells, or the similar imatinib TNT-response observed 
in both Kcl-22 and K562. However, we cannot rule out that 
similar modulation of related GTPases may explain the dif-
ference in nilotinib response between Kcl-22 and K562 cells.
Since IFNα do not specifically inhibit the tyrosine kinase 
activity of BCR-ABL1 like the TKIs, but rather provide dis-
tinct cellular signaling and immune responses toward the 
leukemic cells this could indicate that the TNT formation is 
independent of direct BCR-ABL1 signaling.76,77 To investigate 
the involvement of BCR-ABL1 in TNT formation, we used a 
doxycycline-inducible BCR-ABL1 Ba/F3 cell system. BCR-
ABL1 induction resulted in increased cell rounding compared 
to the Ba/F3 control cells (Figure 4C). Since imatinib treatment 
did not cause an increase in TNT formation in BCR-ABL1 ex-
pressing Ba/F3 cells, but rather in the Ba/F3 cells alone, this 
suggest that the TNT increase most likely involves other fac-
tors besides the inhibition of BCR-ABL1. This was also sup-
ported by the comparison of intracellular signaling by mass 
cytometry, where known BCR-ABL1 downstream targets like 
phospho-STAT-5 and phospho-CrkL 78 were down-regulated 
by the TKI treatments independently of the differences in TNT 
response observed. A similar inhibition of phosphorylated 
STAT-5 and CrkL were observed in both cell lines after ima-
tinib and nilotinib treatment, even though both cell lines have 
significant more TNTs after imatinib treatment, while nilotinib 
only induced TNTs in the Kcl-22 cells (Figure 1A,C). Another 
down-stream BCR-ABL1 target, STAT3 has been suggested to 
play a role in BCR-ABL1 independent resistance in CML,79 as 
well as in IL-10/STAT3 signaling dependent TNT formation 
in a subtype of anti-inflammatory macrophages in tuberculo-
sis and HIV-1 coinfected patients.22 However, in the Kcl-22 or 
K562 cells, the results from the STAT3 signaling in our exper-
iments could not distinguish the changes in signaling observed 
between the TKIs causing an increase in TNT formation ver-
sus those that did not. Based on these observations, we suggest 
that TNT regulation is not modulated directly by BCR-ABL1 
or its kinase activity, however, TNT formation may be modu-
lated by altered cell morphology that is under control of ABL1 
and BCR-ABL1 in selected cell types.
Since IFNα as well as nilotinib were able to increase TNT 
formation in Kcl-22 cells and IFNα previously have been shown 
to restore the ability of CML cells ability to bind to fibronec-
tin through restoration of β1 integrin function, we examined 
β1 integrin as a common feature between the two therapies.46 
Indeed, we found that the change in morphology caused by 
nilotinib, measured by cellular size, were significantly lower 
when pre-incubated with a β1 integrin blocking antibody. Also, 
the induced cell adhesion by both IFNα and nilotinib seemed 
to involve β1 integrin by significantly increasing the average 
distance of cell movement when cells were pre-treated with 
the β1 integrin blocking antibody (Figure 5C,D). The Kcl-22 
cells showed increased movement and more cellular rounding 
after pre-incubation with the  β1 integrin blocking antibody 
(Figure 5A,C,D, Supplemental videos 2-7). Together with 
our observations in the Ba/F3 cells, this supports a hypothesis 
where CML cells adhering poorly to fibronectin results in cell 
rounding and subsequently a lower level of TNT formation. 
The importance of cell attachment to the given substrate and 
capability to form TNTs have previously been shown by others 
and supports our findings.30 Strikingly, nilotinib treatment in 
a Kcl-22(memGFP) subcutaneous mouse model also caused 
a change in cellular morphology and appearance of TNT-like 
structures in the Kcl-22 cells (Figure 6F,G). This demonstrated 
that the morphological changes and TNT modulations found in 
vitro similarly was present in vivo.
When treating bone marrow cells obtained from pa-
tients with chronic phase CML with IFNα and nilotinib, 
no change in TNT numbers or cell morphology where ob-
served (Supplemental Figure 1B-E). BCR-ABL1 expressing 
CML is a model of oncogene driven malignancy, but clearly 
chronic phase CML respond differently than blast crisis 
CML when treated with TKIs. Blast crisis CML patients 
need intensive chemotherapy combined with TKI to secure 
complete remission, before consolidation by hematopoietic 
stem cell transplantation and TKIs maintenance therapy to 
obtain long-term cure.80 It has been shown that blast crisis 
CML has more mutations associated with myeloid malig-
nancies than found in chronic phase CML, and that blast 
crisis cells contain higher level of BCR-ABL1 mRNA.81 In 
vitro, primary chronic phase cells are not particularly sen-
sitive to TKIs,82 and therefore patient-derived blast crisis 
cells have been used in development of new kinase inhibi-
tors for chronic phase CML.83 Our study has examined the 
TKI effect in various CML models, and our observations 
on Kcl-22 and K562 cells could mostly be relevant for blast 
crisis CML. However, we hypothesize that various CML 
myeloid progenitors and more differentiated myeloid CML 
cells in chronic phase disease are involved in TNT forma-
tion in vivo under TKI and IFNα therapy, particularly since 
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the CML cells interacts with a wide repertoire of stromal 
and host cells at various anatomical locations.11,84
Chronic myeloid leukemia with its pathognomonic 
BCR-ABL1 fusion protein is one of several myeloid neo-
plastic diseases that originate from hematopoietic stem 
cells,85,86 and in which the malignant cell has a close re-
lation to mesenchymal support cells in the bone marrow. 
TNTs are proposed as one mechanism of interaction be-
tween mesenchymal stromal cells and leukemic cells in 
the leukemic stem cell niche.29,68,87,88 Kolba and cowork-
ers showed that stromal cells transferred vesicles through 
TNTs to K562 cells and that transfer of vesicles correlated 
with increased resistance toward imatinib treatment.43 This 
underscores the importance of interaction between CML 
cells, mesenchymal stromal cells and  the bone marrow 
niche, a system of cell-to-cell communication that include 
secreted factors, extracellular matrix interactions and di-
rect cell-to-cell interactions.89-93 This leukemic-mesen-
chymal interaction has led to models for leukemogenesis 
that involve bidirectional interactions.94-96 Our data focus 
on inter-leukemic cell communication by TNT and likely 
this play a functional role since leukemic cells are found in 
niches and aggregates in the bone marrow. However, it is 
highly plausible that TNT formation related to CML cells 
play a more significant role with respect to cell-to-cell in-
teraction with the numerous cell types in the bone marrow 
microenvironment as demonstrated by Kolba and cowork-
ers.43 We speculate that hibernating CML cells, only de-
tected by sensitive BCR-ABL1 PCR of the bone marrow, 
through their TNT connections with stromal cells, may or 
may not cause relapse years after treatment.97
In conclusion, kinase inhibitors or IFNα-treatment re-
sulted in increased numbers of TNTs in selected blast cri-
sis CML derived cell lines and a similar result was found 
with TNT-like structures in an in vivo Kcl-22 subcutane-
ous mouse model following nilotinib treatment, but not in 
BCR-ABL1 expressing Ba/F3 cells or in BCR-ABL1 posi-
tive cells from chronic phase CML patients. The observed 
increase in TNTs through TKIs and IFNα appear to involve 
β1integrin dependent function and cell adhesion. This 
confirms that TNT formation is contextual to the complex 
regulation of cellular shape and adhesion. Therapeutic re-
sponses to TKIs and IFNα in CML may therefore be more 
dependent on tumor-stroma and cell-cell interactions than 
previously anticipated. A more complete understanding of 
TNT function in leukemogenesis and therapy resistance 
will likely require novel experimental technologies em-
ployed on disease models that reflect the pathophysiology 
of CML.
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